ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0297 • ACR Convergence 2025

    Longitudinal Serum Proteomic Profiles – A Step Closer to Personalized Monitoring in Dermatomyositis

    Natasha Le Blanc1, Marie Hudson1, Ana Cristina Gonzalez Sanchez2, Lina Marcela Diaz Gallo2 and Valerie Leclair3, 1McGill University, Montréal, QC, Canada, 2Karolinska Institutet, Stockholm, Sweden, 3McGill University, Montréal, Canada

    Background/Purpose: Dermatomyositis (DM) is a multisystemic immune mediated disease presenting with heterogeneous clinical features. Disease monitoring in DM relies in part on biomarkers of muscle…
  • Abstract Number: 0392 • ACR Convergence 2025

    Clinical Indicators of Methotrexate Response in Juvenile Idiopathic Arthritis (JIA) and JIA with Uveitis (JIA-U)

    Abigale Jagger1, Mara Becker2, Susan Thompson3, Mekibib Altaye4, John Bohnsack5, Hermine Brunner6, Margaret Chang7, Ashley Cooper8, Stefanie Davidson9, Alexandra Duell6, Bharti Gangwani7, Carl Langefeld10, Melissa Lerman11, Mindy Lo7, Serena Pastore12, Mariia Pavlenko13, Sampath Prahalad14, Megan Quinlan-Waters15, Laura Ramsey16, Grant Schulert6, Gabriele Simonini17, Erin Stahl8, Gabriele Stocco18, Marc Sudman19, Andrea Taddio18, Virginia Miraldi Utz6, Rae Yeung20 and Sheila Angeles-Han1, 1Cincinnati Children's Hospital, Cincinnati, OH, 2Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, NC, 3Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, BLUE ASH, OH, 4Cincinnati Children's Hospital, Cincinnati, 5University of Utah, Salt Lake City, UT, 6Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 7Boston Children's Hospital, Boston, MA, 8Children's Mercy Kansas City, Kansas City, MO, 9University of Pennsylvania/CHOP, Philadelphia, PA, 10Wake Forest University School of Medicine, Winston Salem, NC, 11Children's Hospital of Philadelphia, Philadelphia, PA, 12Institute of Child and Maternal Health - IRCCS "Burlo Garofolo", Trieste, Italy, 13Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, 14Emory + Children's Pediatric Institute, Atlanta, GA, 15Cincinnati Children's Hospital Medical Center, CCHMC, 16Children's Mercy, Kansas City, MO, 17Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy, 18Insitute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy, 19Cincinnati Children's Hospital Medical Center, Cincinnati, 20The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Patients with JIA are at high risk for development of chronic anterior uveitis (CAU), impacting 10-20% of this population. Although methotrexate (MTX) is the…
  • Abstract Number: 0405 • ACR Convergence 2025

    Juvenile Psoriatic Arthritis and Enthesitis-Related Arthritis: 4-Year Results From the JUNIPERA Extension Study

    Hermine Brunner1, Ivan Foeldvari2, Gerd Horneff3, Antonio Mera Varela4, Angelo Ravelli5, Sharonjeet Kaur6, Swapnil Suhas Dahale7, Ruvie Martin8, Daniel Lovell1, Alberto Martini9 and Nicolino Ruperto10, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Hamburger Zentrum fuer Kinder und Jugendrheumatologie, Rheumatology, Hamburg, Germany, 3Asklepios Klinik, Hamburg, Germany, 4Rheumatology Division. Hospital Clínico Universitario de Santiago and Instituto de Investigaciones Sanitarias (IDIS), School of Medicine, Santiago de Compostela, Spain, 5IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, 6Novartis Pharma AG, Basel, Switzerland, 7IQVIA, Mumbai, India, 8Novartis Pharmaceuticals Corporation, East Hanover, NJ, 9Università di Genova, Genova, Italy, 10Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy

    Background/Purpose: Secukinumab demonstrated efficacy and safety in patients with juvenile idiopathic arthritis (JIA), including enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA), for up to…
  • Abstract Number: 0394 • ACR Convergence 2025

    Predictors of quality of Life in a longitudinal cohort of patients with Uveitis, Juvenile Idiopathic Arthritis, and JIA-associated uveitis

    andressa Guariento Ferreira Alves1, Amy Cassedy2, Virginia Miraldi Utz3, Alexandra Duell3, Megan Quinlan-Waters4, Nicole Reitz5, Sheila Angeles-Han6 and Melissa Lerman7, 1The Children's Hospital of Philadelphia, Philadelphia, PA, 2Cincinnati Children's hospital medical center, cincinnati, OH, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Cincinnati Children's Hospital Medical Center, CCHMC, 5Department of Mental Health, St. Louis, MO, 6Cincinnati Children's Hospital, Cincinnati, OH, 7Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Uveitis, juvenile idiopathic arthritis (JIA), and JIA-associated uveitis (JIA-U) greatly influence children's quality of life (QOL). Our aim is to identify demographic, disease, and…
  • Abstract Number: 0400 • ACR Convergence 2025

    Recent Antibiotic Exposure and Response to Treatment of Juvenile Idiopathic Arthritis

    Daniel Horton1, Charu Verma2, Sanika Rege2, Alicia Iizuka2, Matthew Iozzio3, Dawn Koffman3, Stephen Crystal4, Amy Davidow5, Tobias Gerhard2, Lauren Parlett6, Carlos Rose7 and Brian Strom8, 1Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 2Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, NJ, 3Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, 4Rutgers Center for Health Services Research, Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, 5New Jersey Medical School, Newark, NJ, 6Carelon Research, Inc, Wilmington, DE, 7Thomas Jefferson University, Wilmington, DE, 8Rutgers Biomedical and Health Sciences, New Brunswick

    Background/Purpose: Juvenile idiopathic arthritis (JIA), the most common pediatric rheumatic disease, has been tied to microbiome disruption (dysbiosis). Dysbiosis in adults with arthritis affects response…
  • Abstract Number: 0308 • ACR Convergence 2025

    Artificial Intelligence Assisted Extraction of Patient-Reported Pain Outcomes in Osteoarthritis Using Prompt Engineering of Large Language Models

    Jainesh Doshi1, Stephen Batter1, Yiyuan Wu2, Alice Santilli1, Sandhya Kannayiram3, Susan Goodman4 and Bella Mehta5, 1Hospital for Special Surgery, New York, 2Weill Cornell Medicine, New York, NY, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, 4Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 5Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ

    Background/Purpose: Unstructured data in physician notes can be incredibly valuable, especially for understanding patient-reported outcomes (PROs), which are often mentioned in these notes.In this study,…
  • Abstract Number: 0411 • ACR Convergence 2025

    Outcomes in Juvenile Idiopathic Arthritis Based on Geographic Region in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry

    Julia Harris1, Sheetal Vora2, Catherine Bingham3, Cagri Yildirim-Toruner4, Kerry Ferraro5, Erik Friedrichsen6, Katelyn Banschbach7, Jon Burnham8, Danielle Fair9, Mileka Gilbert10, Beth Gottlieb11, Tzielan Lee12, Melissa Mannion13, Edward Oberle14, Nancy Pan15, Natalie Rosenwasser16, Mary Toth17, Jennifer Weiss18 and Esi Morgan16, 1Children's Mercy Kansas City, Overland Park, KS, 2Atrium Health Levine Children's Hospital, Charlotte, NC, 3Penn State Children's Hospital, Hershey, PA, 4Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, 5Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, 6Seattle Children's Hospital, Burien, WA, 7cincinnati Children's hospital, Villa Hills, KY, 8Children's Hospital of Philadelphia, Bryn Mawr, PA, 9Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, 10Medical University of South Carolina, Charleston, SC, 11Cohen Children's Medical Center, Northwell Health, Lake Success, NY, 12Stanford University School of Medicine, Palo Alto, CA, 13University of Alabama at Birmingham, Birmingham, AL, 14Nationwide Children's Hospital, Columbus, OH, 15Hospital for Special Surgery, New York, NY, 16Seattle Children's Hospital, seattle, WA, 17Nemours Foundation, Orlando, FL, 18Joseph M. Sanzari Children's Hospital and Hackensack Meridian School of Medicine, Hackensack, NJ

    Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a learning health network focused on improving healthcare delivery and outcomes in patients with…
  • Abstract Number: 0414 • ACR Convergence 2025

    Predicting JIA-Associated Uveitis Using Tear Fluid Biomarkers: A Prospective Multicenter Study

    Mariia Pavlenko1, Mekibib Altaye2, Hermine Brunner3, Margaret Chang4, Ashley Cooper5, Stefanie Davidson6, Alexandra Duell3, Bharti Gangwani4, Aimee Hersh7, Gary Holland8, Carl Langefeld9, Melissa Lerman10, Mindy Lo4, Virginia Miraldi Utz3, Sampath Prahalad11, Grant Schulert3, Megan Quinlan-Waters12, Erin Stahl5, Edmund Tsui8 and Sheila Angeles-Han13, 1Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, 2Cincinnati Children's Hospital, Cincinnati, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Boston Children's Hospital, Boston, MA, 5Children's Mercy Kansas City, Kansas City, MO, 6Department of Ophthalmology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, Philadelphia, PA, 7University of Utah, Salt Lake City, UT, 8UCLA Jules Stein Eye Institute and the Department of Ophthalmology, UCLA David Geffen School of Medicine, Los Angeles, 9Wake Forest University School of Medicine, Winston Salem, NC, 10Division of Rheumatology, Children's Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, Philadelphia, PA, 11Emory + Children's Pediatric Institute, Atlanta, GA, 12Cincinnati Children's Hospital Medical Center, CCHMC, 13Cincinnati Children's Hospital, Cincinnati, OH

    Background/Purpose: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA) and can lead to vision loss if not detected early. Current clinical…
  • Abstract Number: 0360 • ACR Convergence 2025

    Assessing Content Validity of a New Questionnaire Evaluating Glucocorticoid Toxicity

    Timothy Howell1, anne Skalicky2, Louis Matza1, John Stone3, Martha Stone4, Vijayaraghava Rao5 and Glenn Phillips5, 1evidera, Washington, DC, 2evidera, Seattle, WA, 3Massachusetts General Hospital , Harvard Medical School, Concord, MA, 4Steritas, LLC, Concord, MA, 5argenx, Boston, MA

    Background/Purpose: While glucocorticoids (GCs) are commonly used to treat a range of inflammatory diseases, the burden of toxicities associated with these medications is significant. The…
  • Abstract Number: 0415 • ACR Convergence 2025

    The Impact of Social Vulnerability Index Scores in Pediatric Uveitis

    Minal Aundhia1, Pankaj Rajdeo2, Michael Wagner1, Alexandra Duell1, Megan Quinlan-Waters3, Virginia Miraldi Utz1 and Sheila Angeles-Han4, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Children's Hospital Medical Center, Cincinnati, 3Cincinnati Children's Hospital Medical Center, CCHMC, 4Cincinnati Children's Hospital, Cincinnati, OH

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children with uveitis as the most common extra-articular manifestation. Uveitis can lead to…
  • Abstract Number: 0316 • ACR Convergence 2025

    Increased Synovial Inflammation, Xist Escape Gene Expression and Knee Pain in Females with Osteoarthritis

    Bella Mehta1, Miguel Otero2, Michael Mazzucco3, Jenelys Ruiz-Ortega4, Caryn Hale4, Fuadur Omi4, Syed Henah Balkhi5, Purva Singh3, Samantha Lessard3, Wei Wang4, Maryam Aslam4, Tristan Maerz6, Peter Sculco3, Anne-Marie Malfait7, Xiaoshun Li8, Yiyuan Wu9, Shady Younis10, William Robinson11, Daniel Ramirez12, Edward DiCarlo12 and Dana Orange5, 1Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ, 2Hospital For Special Surgery, New York, 3Hospital For Special Surgery, New York, NY, 4The Rockefeller University, New York, 5The Rockefeller University, New York, NY, 6University of Michigan, Ann Arbor, MI, 7Rush University Medical Center, Chicago, 8Hospital For Special Surgery, Ridgewood, NY, 9Weill Cornell Medicine, New York, NY, 10Stanford University, Stanford, CA, 11Stanford University, Palo Alto, CA, 12Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: MRI evidence of synovitis and bone marrow lesions, but not cartilage degeneration associate with pain in osteoarthritis (OA). In this work, we integrated clinical,…
  • Abstract Number: 0402 • ACR Convergence 2025

    Risk Factors for Anti-Adalimumab Antibody Development in Pediatric Patients Using Adalimumab for Rheumatic Disease and Associated Conditions

    Dawn Gist1, Andrea Ramirez1, Jamie Lai2, Duc Nguyen1 and Kexin Guo1, 1Baylor College of Medicine, Houston, TX, 2Baylor College of Medicine, The Woodlands, TX

    Background/Purpose: Adalimumab is a monoclonal antibody against TNF-α that is commonly used to treat JIA, hidradenitis suppurativa (HS), chronic uveitis, sarcoidosis, and chronic nonbacterial osteomyelitis…
  • Abstract Number: 0354 • ACR Convergence 2025

    Greater Neighborhood Walkability is Associated with Lower Incidence of Hip Fracture in Older, Community-dwelling Women in the United States: The Cardiovascular Health Study

    Rachel Elam1, Petra Buzkova2, Howard Fink3, Joshua Barzilay4, Eric Roseen5, Jane Cauley6, John Robbins7, Laura Carbone1, Gina Lovasi8 and Kenneth Mukamal9, 1Augusta University, Augusta, GA, 2University of Washingon, Seattle, WA, 3University of Minnesota, Minneapolis, MN, 4Kaiser Permanente of Georgia, Atlanta, GA, 5Boston University, Boston, MA, 6University of Pittsburgh, Pittsburgh, PA, 7University of California Davis, Davis, CA, 8Drexel University, Philadelphia, PA, 9Beth Israel Deaconess Medical Center, Brookline, MA

    Background/Purpose: Higher physical activity is linked to reduced fracture risk in older adults, especially for hip fractures. Emerging evidence demonstrates a potential role for the…
  • Abstract Number: 0424 • ACR Convergence 2025

    Juvenile Idiopathic Arthritis Mimics: A Case Series on Progressive Pseudo-Rheumatoid Dysplasia and CACP Syndrome in Pediatric Patients from a Tertiary Center in South India

    Sreelekha Kambhampati1, keerthi vardhan yerram2, Kavitha Meesala1, Phani Kumar Devarasetti2 and Liza rajasekhar3, 1Nizams institute of medical sciences, hyderabad, India, 2Nizams institute of medical sciences, hyderabad, Andhra Pradesh, India, 3Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most prevalent chronic arthritis in children, but its diagnosis is often challenging due to overlapping symptoms with other…
  • Abstract Number: 0425 • ACR Convergence 2025

    High Density Lipoprotein Dysfunction in Juvenile Idiopathic Arthritis as Compared to Children without Rheumatologic Disease

    Tahnee Spoden1, Samira Nazzar Romero2, Deborah McCurdy3, Alice Hoftman4, Sangmee Bae5, Jennifer Wang4, Ani Shahbazian4 and Christina Charles-Schoeman6, 1UCLA, Los Angeles, CA, 2Nemours Children's Health, Orlando, 3UCLA Medical Center, Los Angeles, CA, 4UCLA, Los Angeles, 5UCLA Rheumatology, Los Angeles, CA, 6UCLA Medical Center, Santa Monica, CA

    Background/Purpose: Cardiovascular disease remains the leading cause of mortality in patients with Rheumatoid Arthritis (RA). Normally, high density lipoprotein (HDL) acts in a cardioprotective capacity…
  • « Previous Page
  • 1
  • …
  • 146
  • 147
  • 148
  • 149
  • 150
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology